Non-nucleoside reverse transcriptase inhibitors in the treatment of human immunodeficiency virus infection

Bibliography

• The Status and Trends of the Global HIV/AIDS Pandemic. Official Satellite Symposium, International AIDS Conference, Vancouver, British Columbia (5–6 July 1996). http://www.unaids.org/highband/document/epidemio/status.html An excellent WWW site for up-to-date epidemiological information about the pandemic.
   Google Scholar
• WEI X, GHOSH SK, TAYLOR ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 373:117–122.
   PubMed Web of Science ®Google Scholar
• One of the two pivotal studies describing viral dynamics in HIV infection.
   Google Scholar
• HO DD, NEUMANN AU, PERELSON AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 373:123-126.One of the two pivotal studies describing viral dynamics in HIV infection.
   Google Scholar
• CARPENTER CCJ, FISCHL MA, HAMMER SM, et al.: Antiretroviral therapy for HIV infection in 1996. JAMA (1996) 276:146–154.
   PubMed Web of Science ®Google Scholar
• The most recent consensus statement from a panel of experts describing current guidelines for treatment of HIV infection.
   Google Scholar
• MARKOWITZ M, SAAG M, POWDERLY WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl. J. Med. (1995) 333:1534-1539. An early clinical trial with ritonavir.
   Google Scholar
• GULICK R, MELLORS J, HAVLIR D, et al.: Potent and sustained antiretroviral activity of indinavir (IDV), Adovudine (ZDV) and lamivudine (3TC). In: Program and Abstracts of the XI International Conference on AIDS. Vancouver, British Columbia (7–12 July 1996). Abstract Th.B.931. Clinical trial showing potency of indinavir in combination.
   Google Scholar
• KOVACS JA, BASELER M, DEWAR RJ, et al.: Increases in CD4 T-lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency syndrome: a preliminary study. New Engl. J Med. (1995) 332:567-575. The first clinical trial using interleukin-2 in HIV-infected patients.
   PubMedGoogle Scholar
• BOUCHER C, NUHUIS M, SCHIPPER P, et al.: Detection of drug sensitive infectious HIV-1 after one year of ritonavir treatment in a patient with persistent undetectable plasma HIV-1 RNA. In: Abstracts of the Fifth International Workshop on HIV Drug Resistance. Whistler, British Columbia (3–6 July 1996). Abstract 70.
   Google Scholar
• RICHMAN DD: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Agents Chemother. (1993) 37:1207-1213. An expert in the field discussing viral resistance.
   PubMedGoogle Scholar
• DEEKS SG, SMITH M, HOLODNIY M, KAHN JO: HIV-1 protease inhibitors. JAMA (1997) 277:145–153.
   PubMed Web of Science ®Google Scholar
• Comprehensive and current review of HIV protease inhibitors.
   Google Scholar
• Update: Provisional Public Health Service recommendations for chemoprophylaxis after occu- pational exposure to HIV. MMWR (1996) 45:468-472.Current guidelines for post-exposure prophylaxis.
   Google Scholar
• COHEN J: The marketplace of HIV/AIDS $. Science (1996) 272:1880–1881.
   PubMed Web of Science ®Google Scholar
• A review of important information about the HIV therapy marketplace.
   Google Scholar
• ROBERTS NA, MARTIN JA, KINCHINGTON D, et al.: Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 248:358–361.
   PubMedGoogle Scholar
• NOWAK M: HIV mutation rate. Nature (1990) 347:522.
   PubMed Web of Science ®Google Scholar
• PANTALEO G, GRAZIOSI C, DEMAREST JM, et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 362:355-358. A seminal study of the importance of HIV in tissues.
   PubMedGoogle Scholar
• EMBRETSO N, ZUPANCIC M, RIBAS JL, et al.: Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period. Nature (1993) 362:359–362.
   PubMed Web of Science ®Google Scholar
• ABOULKER J-P, SWART AM: Preliminary analysis of the Concorde trial. Lancet (1993) 341:889– 890.
   PubMedGoogle Scholar
• A major European study showing the lack of impact of monotherapy in HIV disease.
   Google Scholar
• VOLBERDING PA, LAGAKOS SW, GRIMES JM, et al.: The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trial Group. JAMA (1994) 272:437–442.
   PubMed Web of Science ®Google Scholar
• A major US study showing the lack of impact of monotherapy in HIV disease.
   Google Scholar
• MERLUZZI VJ, HARGRAVE KD, LABADIA M, et al.: Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science (1990) 250:1411–1413.
   PubMedGoogle Scholar
• PAUWELS R, ANDRIES K, DESMYTER J, et al.: Potent and selective inhibition of HIV-1 replication by a novel series of TIBO derivatives. Nature (1990) 343:470–474.
   PubMedGoogle Scholar
• BABA M, DECLERCQ E, IIDA S, et al.: Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives. Antimicrob. Agents Chemother. (1990) 34:2358–2363.
   PubMed Web of Science ®Google Scholar
• GOLDMAN ME, NUNBERG JH, O'BRIEN JA, et al.: Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA (1991) 88:6863–6867.
   PubMed Web of Science ®Google Scholar
• GOLDMAN ME, O'BRIEN JA, RUFFING TL, et al.: L-696,229 specifically inhibits human immu-nodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob. Agents Chemother. (1992) 36:1019–1023.
   Web of Science ®Google Scholar
• DUEWEKE TJ, POPPE SM, ROMERO DL, et al.: U-90152, a potent inhibitor of human immunode-ficiency virus type 1 replication. Antimicrob. Agents Chemother. (1993) 37:1127–1131.
   PubMed Web of Science ®Google Scholar
• BABA M, DE CLERCQ E, TANAKA H, et al.: Potent and selective inhibition of human immu-nodeficiency virus type! by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA (1991) 88:2356–2360.
   PubMed Web of Science ®Google Scholar
• BABA M, DE CLERCQ E, TANAKA H, et al.: Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acydouridine derivatives. Mol. Pharmacol. (1991) 39:805–810.
   PubMed Web of Science ®Google Scholar
• RICHMAN D, ROSENTHAL AS, SKOOG M, et al.: BI-RG-587 is active against zidovudine-resis-tant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. (1991) 35:305–308.
   PubMed Web of Science ®Google Scholar
• CAMPBELL TB, YOUNG RK, ERON JJ, et al.: Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atervidine (U-87201E) in combination with zidovudine or didanosine. J. Infect. Dis. (1993) 168:318–326.
   PubMed Web of Science ®Google Scholar
• HAVLIR D: Antiretroviral therapy: update on non-nucleoside reverse transcriptase inhibitors (NNRTI). Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (4–7 October 1994):279, 19.
   Google Scholar
• ROMERO DL, BUSSO M, TAN CK, et al.: Non-nucleoside reverse transcriptase inhibitors that potently and specifically block HIV-1 replication. Proc. Natl. Acad. Sci. USA (1991) 88:8806–8810.
   PubMed Web of Science ®Google Scholar
• WU JC, WARREN TC, ADAMS J, et al.: A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a non-substrate binding site. Biochemistry (1991) 30:2022–2026.
   PubMed Web of Science ®Google Scholar
• KHOLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZ TA: Crystal structure at 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256:1783–1790.
   PubMed Web of Science ®Google Scholar
• The ground-breaking study demonstrating the structure of HIV reverse transcriptase.
   Google Scholar
• RICHMAN D, SHIH CK, LOWY I, et al.: Human immunodeficiency virus type! mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA (1991) 88:11241–11245.
   PubMed Web of Science ®Google Scholar
• An excellent review of the problems of viral resistance to NNRTIs.
   Google Scholar
• RICHMAN DD: Loss of nevirapine activity associated with the emergence of resistance in clinical trials. In: Abstracts of the Eighth International Conference on AIDS/STD World Congress (Volume 2). Amsterdam (19–24 July 1992). Congrex, Amsterdam (1992). Abstract B183.
   Google Scholar
• DECLERCQ E: Chemotherapy of the acquired immunodeficiency syndrome (AIDS); non-nucleo-side inhibitors of the human immunodeficiency virus type 1 reverse transcriptase. Int. J. Immu-nopharmacol. (1991) 13:83–89.
   PubMed Web of Science ®Google Scholar
• HAVLIR D, CHEESEMAN SH, MCLAUGHLIN M, et al.: High-dose nevirapine: safety, pharma-cokinetics and antiviral effect in patients with human immunodeficiency virus infection. I Infect. Dis. (1995) 171:537–545.
   Google Scholar
• ACTG 241 AND DAVEY RT, CHAITT DG, REED GF, et al.: Randomized, controlled Phase PH trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type-1 infected individuals. Antimicrob. Agents Chemother. (1996) 40:1657–1664.
   PubMed Web of Science ®Google Scholar
• The first published clinical trial showing the efficacy of delavirdine.
   Google Scholar
• MONTANER J: Symposium at the International AIDS Conference. Vancouver, British Columbia (1 July 1996). Published in Journal of the International Association of Physicians in AIDS Care (1996) 2:11–13.
   PubMedGoogle Scholar
• CONNOR EM, SPERLING RS, GELBER R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with Adovudine. New Engl. J Med. (1994) 331:1173-1180.The pivotal trial of reduction of perinatal transmission of HIV using ZDV that has formed the basis of recent recommendations.
   Google Scholar
• CDC: Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988 - August 1994. MMWR (1995) 44:929–933.
   PubMedGoogle Scholar
• CHEESEMAN SH, et al.: Safety of high dose nevirapine after 200 mg/d lead-in. IX International Conference on AIDS/IV STD World Congress. Berlin (6–11 June 1993). Abstract PO-B26-2109.
   Google Scholar
• SAAG MS, EMINI EA, LASKIN OL, et al.: A short-term clinical evaluation of L697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. New Engl. J Med. (1993) 329:1065–1072.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI et al.: A double-blind randomized trial for safety, clinical efficacy, biological activity and susceptibility testing in 120 HIV positive patients treated with L,697,661, AZT and combinations of both drugs. IX International Conference on AIDS/IV STD World Congress. Berlin (6–11 June 1993). Abstract WS-B26-4.
   Google Scholar
• BYRNES VW, et al.: Combination therapy with AZT prevents selection of HIV-1 variants that are highly resistant to the non-nucleoside inhibitor, L,697,661. IX International Conference on AIDS/IV STD World Congress. Berlin (6–11 June 1993). Abstract WS-A19-5.
   Google Scholar
• SPENCE RA, JOHNSON KA: Therapeutic potential of non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection. Exp. Opin. Invest. Drugs (1996) 5(8):985–1001.
   Google Scholar
• An excellent and current review.
   Google Scholar